Bodi Envi blog: Guides, page 2
Plain, sourced writing on GLP-1 treatment: what the FDA-approved labels and the trials say, what compounded medication is and is not, what things cost, and how to choose a program.
- Guide
Nausea on semaglutide: what the label says and what helps
How often the Wegovy® label reports nausea and when, why it happens, what a provider may do, the steps published sources support, and when to seek care.
- Guide
Buying compounded GLP-1 medication online safely
What to verify before you order, as the FDA's BeSafeRx campaign and LegitScript describe it, the red flags the FDA names, and how to compare prices.
- Guide
Using the Bodi Envi patient portal
What Bodi Envi publishes about its patient portal at patient.bodienvi.com, logging in, messaging your care team, treatment monitoring and cancellation requests.
- Guide
Semaglutide, pregnancy and fertility: what the label says
What the Wegovy® label says about pregnancy, stopping before a planned pregnancy and breastfeeding, and what the Zepbound® label says about oral contraceptives.
- Guide
Semaglutide, tirzepatide and sleep apnea
Zepbound® is FDA-approved for moderate to severe sleep apnea in adults with obesity and semaglutide is not. What the label and SURMOUNT-OSA found.
- Guide
Semaglutide vs tirzepatide: how the two compare
How semaglutide and tirzepatide differ in mechanism, dosing, side effects, trial results and cost at Bodi Envi, and why a licensed provider makes the choice.
- Guide
Semaglutide over time: what the trials measured
How STEP 1 was structured over 68 weeks, what it measured at the end and how widely results varied, and what the extension found after treatment stopped.
- Guide
GLP-1 side effects: what the labels report
Every side effect the Wegovy® and Zepbound® labels report, with frequencies, why the labels say they happen, what a provider may do, and when to seek care.
- Guide
What happens when you stop semaglutide or tirzepatide
What the STEP 1 extension and SURMOUNT-4 found after treatment stopped, what the labels say about missed doses, and how to raise stopping with a provider.
- Guide
How tirzepatide works
How tirzepatide acts on the GIP and GLP-1 receptors as the Zepbound® label describes it, what SURMOUNT-1 found over 72 weeks, and what a provider weighs.
- Guide
Tirzepatide and menopause
The Zepbound® label does not mention menopause. Who was in SURMOUNT-1 by sex and age, what a 2026 review says about sex and response, and what to ask.
- Guide
Tirzepatide side effects per the Zepbound® label
The side effects the Zepbound® label reports for tirzepatide by dose, when they occur, why, what a provider may do and when to seek care.
- Guide
Traveling with tirzepatide
What the Zepbound® label allows at room temperature, what the TSA says about medication at screening, and how to plan doses across a trip.
- Guide
Eating too little on a GLP-1 medication
What the labels warn about dehydration and kidney injury from reduced intake, what 2026 reviews report on meal size and muscle, and when to tell your provider.
- Guide
Eating well on tirzepatide, including plant based
What the Zepbound® label says about diet, what the Dietary Guidelines for Americans recommend, and what published reviews say about plant based eating.
- Guide
Not losing weight on tirzepatide: what to consider
How much results varied in SURMOUNT-1, what the Zepbound® label says about escalation and dose, what predicts response, and what to raise with a provider.
Start with an online assessment.
Answer a few questions about your health and goals. A licensed provider reviews your answers and decides whether treatment is appropriate for you.
